FDA grants fast-track status to GI ARS drug by Soligenix

01/31/2013 | Pharmaceutical Business Review Online

Soligenix's OrbeShield obtained fast-track designation from the FDA as treatment for gastrointestinal acute radiation syndrome. The drug has already won orphan-drug status to prevent death after a lethal or high dose of irradiation from a disaster.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN